Drug Type Small molecule drug |
Synonyms MIN 117, WF-516, WF516 |
Mechanism 5-HT1A receptor antagonists(Serotonin 1a (5-HT1a) receptor antagonists), 5-HT2A receptor antagonists(Serotonin 2a (5-HT2a) receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC25H26Cl3N3O4 |
InChIKeyHRNDUKHBCUTNAL-FERBBOLQSA-N |
CAS Registry310392-93-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | MIN-117 | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Depressive Disorder, Major | Phase 2 | US | 30 Mar 2018 | |
Depressive Disorder, Major | Phase 2 | BG | 30 Mar 2018 | |
Depressive Disorder, Major | Phase 2 | FI | 30 Mar 2018 | |
Depressive Disorder, Major | Phase 2 | GE | 30 Mar 2018 | |
Depressive Disorder, Major | Phase 2 | MD | 30 Mar 2018 | |
Depressive Disorder, Major | Phase 2 | PL | 30 Mar 2018 | |
Depressive Disorder, Major | Phase 2 | UA | 30 Mar 2018 | |
Depressive Disorder | Phase 2 | - | - | |
Depressive Disorder | Phase 2 | - | - | |
Pain | Preclinical | US | 14 Nov 2018 |
Phase 2 | 360 | (5.0 mg MIN-117) | zqgdvglsdt(gzqvqkdgdz) = leytguuspr nkkkecuqvc (falpburhmx, btzavtdsps - fzfocnvnih) View more | - | 17 Dec 2020 | ||
(2.5 mg MIN-117) | zqgdvglsdt(gzqvqkdgdz) = jyacdjzbdy nkkkecuqvc (falpburhmx, wskroyryof - tmywxubxze) View more |